Table 2.
Correlation between KIF20A expression and the clinicopathological features of epithelial ovarian cancer
| Characteristic | Total | KIF20A expression
|
Chi- square test P-value | Fisher’s exact test P-value | ||
|---|---|---|---|---|---|---|
| None/Weak | Moderate/Strong | |||||
| Age (years) | ≤53 | 81 | 33 (22.0) | 48 (32.0) | 0.841 | 0.869 |
| >53 | 69 | 27 (18.0) | 42 (28) | |||
| Histological type | Serous adenocarcinoma | 119 | 46 (31.1) | 73 (49.3) | 0.114 | – |
| Mucoid adenocarcinoma | 24 | 10 (6.7) | 14 (9.5) | |||
| Endometrial adenocarcinoma | 3 | 3 (2.0) | 0 (0) | |||
| Clear cell carcinoma | 2 | 0 (0) | 2 (1.3) | |||
| FIGO stage | I | 25 | 15 (11.1) | 10 (6.8) | 0.008 | – |
| II | 18 | 11 (8.1) | 7 (5.2) | |||
| III | 83 | 28 (20.7) | 55 (40.7) | |||
| IV | 9 | 1 (0.7) | 8 (5.9) | |||
| Lymph node metastasis | Absent | 71 | 37 (29.4) | 34 (27.0) | 0.002 | 0.003 |
| Present | 55 | 14 (11.1) | 41 (32.5) | |||
| Intraperitoneal metastasis | No | 56 | 35 (23.3) | 21 (14.0) | <0.001 | <0.001 |
| Yes | 94 | 25 (16.7) | 69 (46.0) | |||
| Intestinal metastasis | No | 68 | 30 (21.6) | 38 (27.3) | 0.283 | 0.303 |
| Yes | 71 | 25 (18.0) | 46 (33.1) | |||
| Vital status at last follow-up | Alive | 69 | 45 (30.0) | 24 (16.0) | <0.001 | <0.001 |
| Dead | 81 | 15 (10.0) | 66 (44.0) | |||
| Intraperitoneal recurrence | No | 69 | 37 (37.3) | 32 (32.3) | 0.030 | 0.048 |
| Yes | 30 | 9 (9.1) | 21 (21.2) | |||
| Distant recurrence | No | 35 | 11 (19.0) | 24 (41.4) | 0.546 | 0.583 |
| Yes | 23 | 9 (15.5) | 14 (24.1) | |||
| Tumor recurrence | No | 60 | 32 (21.5) | 28 (18.8) | 0.005 | 0.006 |
| Yes | 89 | 27 (18.8) | 62 (29.0) | |||
| Residual tumor size (cm) | ≤1 | 98 | 42 (32.6) | 56 (43.4) | 0.467 | 0.534 |
| >1 | 31 | 11 (8.5) | 20 (15.5) | |||
| Differentiation grade | G1/G2 | 64 | 25 (19.8) | 39 (31.0) | 0.743 | 0.856 |
| G3 | 62 | 26 (20.6) | 36 (28.6) | |||
| Neoadjuvant chemotherapy | No | 113 | 50 (33.3) | 63 (42.0) | 0.063 | 0.082 |
| Yes | 37 | 10 (6.7) | 27 (18.0) | |||
| Postoperative chemotherapy | No | 7 | 3 (2.0) | 4 (2.7) | 0.724 | 1.000 |
| Yes | 143 | 58 (38.7) | 85 (56.7) | |||
| Drug resistance | No | 30 | 15 (26.3) | 15 (26.3) | 0.013 | 0.025 |
| Yes | 27 | 5 (8.8) | 22 (38.6) | |||
| HIPEC | No | 108 | 46 (33.3) | 62 (44.9) | 0.213 | 0.292 |
| Yes | 30 | 9 (6.5) | 21 (15.2) | |||
| Ascites with tumor cells | No | 44 | 27 (27.6) | 14 (14.3) | <0.001 | <0.001 |
| Yes | 54 | 13 (13.3) | 41 (41.8) | |||
| Cytoreductive surgery | No | 26 | 10 (6.7) | 16 (10.7) | 0.860 | 1.000 |
| Yes | 124 | 50 (33.3) | 74 (49.3) | |||
| CA125 (U/mL) | ≤35 | 7 | 2 (1.5) | 5 (3.7) | 0.568 | 0.706 |
| >35 | 127 | 50 (37.3) | 77 (57.5) | |||
| CA199 (U/mL) | ≤35 | 93 | 33 (24.6) | 60 (44.8) | 0.147 | 0.180 |
| >35 | 41 | 20 (14.9) | 21 (15.7) | |||
| CA153 (U/mL) | ≤25 | 27 | 13 (11.0) | 14 (11.9) | 0.223 | 0.262 |
| >25 | 91 | 32 (27.1) | 59 (50.0) | |||
| NSE (U/mL) | ≤15.2 | 31 | 10 (11.9) | 21 (25.0) | 0.313 | 0.361 |
| >15.2 | 53 | 23 (27.4) | 30 (35.7) | |||
| CEA (U/mL) | ≤5.0 | 90 | 39 (34.5) | 51 (45.1) | 0.132 | 0.157 |
| >5.0 | 23 | 6 (5.3) | 17 (15.0) | |||
| β-HCG (U/mL) | ≤3.0 | 54 | 21 (31.3) | 33 (49.3) | 0.977 | 1.000 |
| >3.0 | 13 | 5 (7.5) | 8 (11.9) | |||
Abbreviations: β-HCG, β human choriogonadotropin; CEA, carcinoembryonic antigen; FIGO, International Federation of Gynecology and Obstetrics stage; HIPEC, hyperthermic intraperitoneal chemotherapy; NSE, neuron-specific enolase.